INTRODUCTION
============

Bone defects due to trauma, developmental anomalies, oncological resections, infections or lesions necessitate reconstructive methods for substitution of lost supportive tissues for which different bone graft materials are available. These materials promote the bone-healing response through provision of osteogenic, osteoconductive and osteoinductive activities. Bone graft materials have been divided into autografts, allografts, xenografts, synthetic materials or a combination of them each with specific characteristics^i^. Autograft is the gold standard forbone grafts, refers to the bone tissues harvested from an individual's iliac crest, femur or tibia and is implanted in the same person. Due to the limitations of autografts such as significant donor-site, morbidity, extended operating room time and limited quantity and quality of bone available for harvest, a variety of synthetic and bioimplants have been developed as bone substitutes. Allograft, an alternative to autograft, is a tissue harvested from an individual implanted into another one of the same species. Xenograft, is a bone tissue harvested and implanted into different species while synthetic materials are various extracted or synthesized protein growth factors, adhesion molecules or synthetic osteoconductive materials which are available for bone graft purposes\[[@b1-jod-9-116]\].Synthetic materialsvary greatly in osteoconductivity, osteoinductivity, mechanical strength, handling properties or cost while newly developed materials are constantly made available with improved properties. Biologic acceptability, predictability, clinical feasibility, minimal operative sequel, postoperative sequel and patient acceptance are of the basic principles mentioned for bone graft materials \[[@b2-jod-9-116]\].Up to now, no ideal bone graft material has been developed owning all required properties. Therefore, assessment of different bone graft materials is of primary importance prior to their clinical usage. Based on the studies performed, animal studies on dog, rabbit, monkey, rat or horse may possibly clarify the tissue response to different graft materials.

Bio-Oss®, anosteoconductive bone substitute, has been introduced to promote bone growth in the periodontal and maxillofacial osseous defects including mineral bovine bone (xenograft). Bio-Oss® has been claimed to promote formation of new cement, functional periodontal ligaments and alveolar bone preserving osteoconduction \[[@b3-jod-9-116],[@b4-jod-9-116]\].

Bio-Oss® has been used in different areas such as periodontology and intrabony defects\[[@b5-jod-9-116]\], peri-implant defects\[[@b6-jod-9-116]\], sinus floor augmentation\[[@b7-jod-9-116],[@b8-jod-9-116],[@b9-jod-9-116]\],ridge preservation\[[@b10-jod-9-116],[@b11-jod-9-116]\], ridge augmentation\[[@b12-jod-9-116],[@b13-jod-9-116]\] and ridge reconstruction \[[@b14-jod-9-116]\]. The similar natural starting material together with the complex patented manufacturing procedures are the resemblances of Bio-Oss® to the human natural bone. Its higher porosity, as human natural bone increases blood vessel formation and bone cell migration through a coarse-meshed interconnecting pore system \[[@b15-jod-9-116]\], which is a good meshwork for osteogenic cells and possibly willencourageosteoblastic differentiation and matrix synthesis \[[@b16-jod-9-116]\]. Demineralized bone matrix (DBM), another potential alternative supplement for autogenous bone graft, possesses osteoconductive characteristics with a possible osteoinductive property. It has been widely used in different fields of orthopedics, neurosurgery, plastic surgery and dentistry and it has been extensively investigated as a material to induce new bone formation. The osteoinductive characteristics of DBM is possibly due to the existence of matrix-associated bone morphogenetic proteins (BMPs) such as BMP2, BMP4 or BMP7 and growth factors such as TGF-β available in the host environment during the demineralization process\[[@b17-jod-9-116]\]. Demineralized bone matrix does not contain osteoprogenitor cells although it facilitates the recruitment of the progenitor cells from the bone marrow to the defects called as osteoinductive property\[[@b18-jod-9-116]\].Furthermore, demineralized bone matrix has been shown to possess high osteoinductive properties improving the integration of autogenous bone grafts in the skull \[[@b19-jod-9-116]\].

In the recent years, different DBMs have been introduced for the clinical uses of bone healing with different capabilities for the used processing or carrier media. Then, the materials' weaknesses and strengths must be taken into account in the clinical environment and the clinician should select the most effective DBM to gain access to the best outcomes \[[@b20-jod-9-116]\]. Different processing and donor variability caused DBMs to show variable osteoinductive activity \[[@b21-jod-9-116]\].

The factors possibly influencing DBM's osteoinductive activity are the matrix geometry (particle size) \[[@b22-jod-9-116]\], the time to harvest and the age of the donor \[[@b23-jod-9-116]\]. Due to the poor handling properties of DBM granules, most commercially available DBMs contain inert carriers such as glycerol, hyaluronicacid or reverse phase polymers, which reduce the DBM content. Accell Connexus^®^ is a 2nd generation demineralized bone matrix (DBM) product. Accell Connexus combines DBM and poloxamer Reverse Phase Medium with Accell Bone Matrix (ABM). This patented, dispersed form of DBM offers significantly increased surface area, which provides access to natural bone proteins \[[@b24-jod-9-116]\]. As Accell uses a processed form of DBM as its carrier, the carrier itself is expected to be osteoinductive, resulting in the implant being 100% DBM, which should increase bone repair outcome compared with DBM bioimplants containing DBM in an inert carrier \[[@b25-jod-9-116]\]. The purpose of the present study was to histologically evaluate the efficacy of Accell Connexus^®^ and Bio-Oss® on the quality and bone healing rate in the experimental defects on rabbit calvarium. The main hypothesis of this study was that the osseoinductivity of Accell Connexus^®^ would promote more bone formation than Bio-Oss®.

MATERIALS AND METHODS
=====================

In this interventional animal study, 12 healthy 2.5--3.5 kg weighing male New Zealand white rabbits were used.

The study was approved according to the protocol of the University ofTehran Animal Care Ethics Committee. The animals were obtained from Pasteur Institute, Iran while their healthiness was approved by a veterinary surgeon.

The animals were placed under general anesthesia with an intramuscular injection of 35 mg/kg ketamin 10% and 2 mg/kg xylazine 2%. The fur was shaved over the cranium region while the surgical site was prepped and draped with betadin scrub 7% for 5 minutes. An incision was made from the anterior to posterior with a number 15 blade cranio-caudally and the skin and periosteum were reflected with Glickman elevator. Three 3×6mm defects that could tried to be like as a infra bony periodontal defects were made in each rabbit calvarium with a 3 mm bur while the surgical sites were irrigated with the sterile saline to prevent overheating during the surgical procedure. In addition, the periodontal probe was carefully used to assess the created defects and to ensure each defect to be identical. Anatomical landmarks were also used for determining the ideal place of the defect (occipital process, cranio-caudal suture that transversally separate the frontal bone from parietal bone). The bone substitutes were placed directly into the defectse qual to the volume of the bone removed, while 3 defects were randomly grafted in 3 different ways; one defect filled with Accel Connexus^®^ (Gen Sci Ortho Biologics Inc, Irvine, USA), the second with small (0/2-1mm) particles of Bio-Oss® (Geistlich Pharma AG, Wolhusen; Switzerland) and the last one was left unfilled for spontaneous healing as a control group. To eliminate bias in defect location, the defect fill sequences were as follows: in the first rabbit the defects were treated randomly with the two previously mentioned materials and the third defect was left unfilled. Then these positions were changed rotationally (clockwise) for the other rabbits. All locations were recorded in charts. Then, the periosteum and skin were sutured ollowby degradable sutures 4-0 Vicryl (Ethicon, Johnson & Johnson, USA) and 3-0 monofil polyamide nylon (SINORGMED, without any apparent complications. Shandong, China), respectively. The animals received endrofloxacin 5% intramuscularly for five days as analgesia with keto profen 10% for three days as an antibiotic. Each rabbit was individually caged and received standardized food (Baby Rabbit Pellets®, M-0662, Master feeds, Division, Maple Leaf Mills LTD, London, Ontario, Canada). The animals were divided into three identical groups and were sacrificed at the fourth, sixth and eighth week postoperatively with an intravenous overdose of 10% sodium thiopental in the auricular vein.

Histological Process
--------------------

After sacrifice, the entire cranial vault was carefully removed from each animal leaving the pericranium intact.

The specimens were placed for fixation in 10% formalin for at least a week and storedin 10% formic acid for decalcification for 10 days afterwards. Following visual inspections, it was tried to select blocks of similar regions with 1mm margins of the surrounded native bone; then, the specimens were set in lithium carbonate for 10 minutes; subsequently set in formalin solution for 24 hours.

The blocks were coded and sent for histological analysis to the pathologist who was blind to the materials used in the defects.

The blocks were embedded in paraffin and sectioned. All sections were stained with hematoxylin-eosin (H&E) for light microscopy assessments. From each block, 5μm thick sections were obtained. Inflammation intensity, foreign body reaction, trabeculation thickness and Regenerated bone type (woven, woven + lamellar, lamellar) were examined by the light microscope (BX40, Olympuse, Japan).

Although foreign body reaction was only examined by the presence or absence of foreign body giant cells in a granulomatous response in the specimens, the inflammation intensity was classified into three grades according to lymphocytic infiltration around the bone graft materials in the examined defects, as mentioned below: Negative (no inflammation):0--100 lymphocytesMild (mild inflammation):100--500 lymphocytesModerate to severe (moderate to severe inflammation): over 500 lymphocytes.

The polarized light microscope divided regenerated bone type in to three scores: 1-lamellar 2-lamellar- woven 3-woven.

Furthermore, trabeculation thickness analysis was completed using an eyepiece graticule with 40× magnification classifying it into three divisions of thin (less than 20 μm), moderate (20--60 μm) and thick (more than 60 μm).

The obtained data were subjected to Mann-Whitney U test.

RESULTS
=======

Inflammation intensity and foreign body reaction
------------------------------------------------

In the 4^th^ week specimens, no inflammation was observed in Bio-Oss® defects while in 6- and 8th week specimens, three cases (75%) showed no inflammatory response and only one case (25%) demonstrated mild inflammation.

In DBM-filled defects, there was one mild inflammation (25%) and three severe inflammatory reactions (75%) in the three-time interval analyses. No inflammatory responses were noted in the control specimens ([Table 1](#t1-jod-9-116){ref-type="table"}). Significant differences were observed between Bio-Oss® and DBM after four and eight weeks (both ps=0.029). Furthermore, significant differences were noted between DBM and control defects in all time intervals (all ps=0.029).

Bio-Oss® and control specimens showed no positive foreign body reactions while all DBM specimens were positive regarding this reaction in all three time intervals ([Figures 1](#f1-jod-9-116){ref-type="fig"}&[2](#f2-jod-9-116){ref-type="fig"}). Furthermore, all DBM and Bio-Oss® defects showed remained biomaterials and a few resorptions.

Trabeculation Thickness
-----------------------

### The 4th week

Regarding Bio-Oss® specimens; one case (25%) showed trabeculation thickness of 20--60 μm, two cases (50%) had less than 20 μm thickness and one case (25%) had not initiatedossification. In the controls, two cases (50%) showed a thickness of more than 60 μm, one case (25%) showed 20--60 μm thickness and one case (25%) had already started ossification. In the DBM group, two cases (50%) had already started ossification and the others (2 cases; 50%) showed a thickness of less than 20μm.

### The 6th week

Bio-Oss® and control specimens showed similar trabeculation thicknesses-three cases (75%) with more than 60 μm thickness and one case (25%) with less than 20 μm thickness to the DBM-filled defects showing less than 20 μm and 20--60 μm thicknesses equally (50% for each).

In the 6th week specimens, the bone formed in the Bio-Oss® group was equally of lamellar or lamellar + woven type (two cases, 50%). There was similar frequency of lamellar + woven and woven b

One in the DBM specimens (two cases, 50%). Furthermore, the frequency of lamellar, lamellar + woven and woven bone types was 25% (one case), 50% (two cases) and 25% (one case) in the control specimens, respectively.

### The 8th week

All control and three (75%) Bio-Oss® specimens showed thicknesses higher than 60 μm and one case (25%) showed 20--60 μm trabeculation thickness.

DBM specimens showed an equal frequency of 20--60 μm and less than 20 μm thicknesses (two cases; 50%) ([Table2](#t2-jod-9-116){ref-type="table"}).

According to the Mann-Whitney test, significant differences only existed between DBM and control defects after the 8th week (P=0.029) with no other significant differences being noted performing paired comparisons in the three time intervals.

Regenerated Bone Type
---------------------

Two experimental defects of (66.7%) Bio-Oss® specimens showed lamellar + woven bone with one case (33.3%) showing woven bone after the 4th week (one started ossification). All controls demonstrated lamellar + woven bone (three cases; 100%) while the bone formed in all DBM specimens were of woven type (three cases; 100%).

In the 8th week, 75% of Bio-Oss® (three cases) specimens showed lamellar and 25% of them (one case) showed lamellar + woven bone type. In the control, all the bone formed was of lamellar type while in the DBM defects, 75% (three cases) lamellar + woven and 25% woven (one case) bone types were observed ([Table 3](#t3-jod-9-116){ref-type="table"}). Significant differences were observed between DBM and control specimens in the 8th week time interval (P=0.029) regarding bone regeneration type while no other significant differences were noted in the paired comparisons between the groups.

With respect to the amount of bone regeneration; the control, Bio-Oss® and DBM groups showed lamellar bone formation in a decreasing order; however, no significant difference was seen (P\>0.05).There was significantly more regenerated lamellar bone at 8 weeks following surgery compared to 4 weeks in the Bio-Oss® group (P\<0.05). This result was not significant for other groups (P*\>*0.05).

DISCUSSION
==========

The healing of craniofacial defects, as an important clinical challenge, received great attention, for which autograph tremainedas the material of choice because it contains three essential elements for bone regeneration (osteogenesis, osteoinductive and osteoconductive). DBM has been used as abone graft substitute for over thirty years because of its biocompatibility, osteoconductive and osteoinductive properties. DBM bio implants contain DBM mixed with aninert carrier to ease handling of the material leading to a decrease in the amount of DBM to 40% or less of the to talimplant volume. It has been shown that the amount of induced new bone by DBM is proportional to the amount of DBM implanted; thus, dilution of DBM with an inert carrier will reduce the properties of the bio implant.

Accell Connexus^®^ has been claimed to have osteoinductive besides osteonconductive properties ;therefore, it is important to evaluate the material before using in the clinic. The present study demonstrated that inflammatory reaction and foreign body reaction significantly increased in DBM as compared to Bio-Oss® and control defects. The presence of slight inflammatory cells in the bio Oss ^®^ group could be indicative of a host reaction to this inert material \[[@b26-jod-9-116]\].Other studies observed no proliferation of inflammatory cells following the application of Bio-Oss^®^ for maxillary sinus augmentation and the rehabilitation of other facial skeletal structures \[[@b27-jod-9-116], [@b28-jod-9-116]\]. Van Osch et al. \[[@b29-jod-9-116]\] used bovine trabecular demineralized bone matrix in the rabbit ear with no problem or sign of increased inflammation or foreign body reactions, which is in consistency with our study which has shown the biocompatiblity of BioOss^®^.

The present authorss peculated the severe inflammation in DBM group that remained constant during the study time could be a robust host reaction to a heterogeneous bone substitute material. In Agnol et al.'sstudy \[[@b30-jod-9-116]\], the superiority of homologous demineralized bone matrix graft to heterogene ousxenograft was indicated. Although no significant differences were noted in the bone properties between Bio-Oss®, DBM and control specimens in all4, 6 and 8 weeks time intervals, we found less lamellar bone in DBM groups in comparison to control and bio -Oss between the study time intervals. These results are consistent with the study of Athanasiouet al.\[[@b31-jod-9-116]\] in which more bone formation was found in the bovine xenograft group compared to the DBM group in experimental defects, which was created in the rabbit's lateral femoral condoyle. Bigham et al. \[[@b32-jod-9-116]\] declared the superior effect of xenograft to DBM group on bone formation based on radiological union. The less bone maturation in the DBM group in comparison to the control groupmight be the surprising part of this study. According to the authors' belief, the thick periosteal layer of rabbitcalvaria, which was carefully sutured during wound closure, may have acted as a natural barrier membrane to induce guided tissue regeneration in the control experimental defects and enhance bone formation. However, the severe inflammation response which possibly concludes to delayed bone formation and/or lower rate of ossification, might be the main reason for less bone maturation in the DBM group. We found less lamellar bone in the DBM than the Bio-Oss^®^ group. Its extrapolated from an in vitro study; the presence of macrophages in combination with blood could not enhance chondrogenesis \[[@b27-jod-9-116]\]. According to the authors state, contrary to Bio-Oss, the applied DBM was in putty shape, so there was no spaces through this bone substitute material for vascular and osteogenic ingrowths that could have resulted in less bone formation and maturation. The presence of macrophage cells and severe inflammation due to host reaction could hamperbone maturation in the DBM group too. In the present study, thickness of the lamellar bone formed in the Bio-Oss--grafted sites was greater than the DBM group, although no statistically significant difference was found. These results are consistent with the previous studies, which have shown Bio-Oss has a proper potential for bone formation \[[@b27-jod-9-116], [@b28-jod-9-116]\]. The porosity and particle shape of Bio-Oss could increase the surface area, which makes Bio-Oss a suitable scaffold for penetration of the cells mediating osteogenesis and angiogenesis \[[@b27-jod-9-116]\]. However, the bone healing properties of Bio-Oss® were supported and superior when compared to the control or autogenousgraft when examined in human maxillary sinus^ii^. Perhaps the biomaterial bone grafts are more effective in the human especially when used in larger defect sizes or critical size defects. On the contrary to our study, DBM osteoinductive property has been confirmed by several studies while others showed it to have bone formation properties following extra-skeletal implantation \[[@b34-jod-9-116]--[@b39-jod-9-116]\]. Rabieet al \[[@b19-jod-9-116]\] reported increased osteogenic properties of a composite of autogenous and DBM when compared to autogenous grafts using human DBM and rabbit DBM (allogeneic demineralized bone matrix). Marusic et al \[[@b40-jod-9-116]\] concluded bone induction with DBM in thymectomized rats to be significantly more than non-thymectomized rats (95% vs. 25%). Furthermore, Wang and Glimcher \[[@b41-jod-9-116]\] showed that bovine DBM-induced bone formation in the rat's cranial defects were less than allogeneic DBM. It has determined the true critical size defect in the rabbit model as 15m; therefore, three critical size defects cannot be created in the rabbit cranium due to the small size of cranium \[[@b42-jod-9-116]\]. Although lamellar bone regeneration will continue until four postoperative months or 12 weeks, others suggested 8 weeks in this regard as studied in the present study \[[@b43-jod-9-116]--[@b46-jod-9-116]\]. Callan et al. (2000) reported that the extensive new bone formation and minimal residual bone graft matrix would be observed at an average of 5 months postoperatively \[[@b44-jod-9-116]\]. The authors' expectations regarding the higher bone maturation rate of DBM compared to Bio-Oss did not turn out to be correct; perhaps the study time intervals, the experimental defect size, the number of the samples and different source and shape of the examined material(allograft putty versusxenograftgranules) have been influential. However, the rabbit is a suitable animal for experimental studies and it is commonly used for medical research. Some of its advantages are that it is easily handled and the cranial defects provide a good first phase bone model for experiments related to bone grafting materials and evaluations of bone regeneration due to the sufficient amount of bone marrow facilitating bone formation \[[@b45-jod-9-116]--[@b47-jod-9-116]\]. Moreover, the rabbit has a larger cranium, which makes it feasible to create several defects in one cranium, which reduces operation time, cost and observational errors among individuals. The remodeling phase in the rabbit is about three times more rapid than in humans; therefore, a healing period of 2 to 4 weeks was considered appropriate to evaluate the stability of the material and the host reactionand 8 weeks or more may be used to assess late healing, such as bone incorporation, resorption of materials, bone remodeling or the amount of bone regeneration \[[@b48-jod-9-116], [@b49-jod-9-116]\].

CONCLUSION
==========

As shown by the present study, Accell Connexus^®^ has a lower rate of ossification and bone healing in comparison to the control and Bio-Oss®, although no significant differences were found.
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###### 

Inflammations Observed in the Defects Filled with Bio-Oss®, DBM or Control

  **Weeks**   **Group**   **Negative**   **Mild**   **Severe**
  ----------- ----------- -------------- ---------- ------------
  **4**       Bio-Oss®    4 (100%)       0          0
  Control     4 (100%)    0              0          
  DBM         0           1 (25%)        3 (75%)    
                                                    
  **6**       Bio-Oss®    3 (75%)        1 (25%)    0
  Control     4 (100%)    0              0          
  DBM         0           1 (25%)        3 (75%)    
                                                    
  **8**       Bio-Oss®    3 (75%)        1 (25%)    0
  Control     4 (100%)    0              0          
  DBM         0           1 (25%)        3 (75%)    

###### 

Trabeculation Thickness Observed in the Defects Filled with Bio-Oss®, DBM or Control

  **Weeks**   **Group**   **Negative**   **Mild**   **Severe**
  ----------- ----------- -------------- ---------- ------------
  **4**       Bio-Oss®    4 (100%)       0          0
  Control     4 (100%)    0              0          
  DBM         0           1 (25%)        3 (75%)    
                                                    
  **6**       Bio-Oss®    3 (75%)        1 (25%)    0
  Control     4 (100%)    0              0          
  DBM         0           1 (25%)        3 (75%)    
                                                    
  **8**       Bio-Oss®    3 (75%)        1 (25%)    0
  Control     4 (100%)    0              0          
  DBM         0           1 (25%)        3 (75%)    

###### 

Bone Regeneration Type Observed in the Defects Filled with Bio-Oss®, DBM or Control

  **Weeks**   **Group**   **Lamellar**   **Lamellar + Woven**   **Woven**
  ----------- ----------- -------------- ---------------------- -----------
  **4**       Bio-Oss®    0              2 (66.7%)              1 (33.3%)
  Control     0           3 (100%)       0                      
  DBM         0           0              2 (100%)               
                                                                
  **6**       Bio-Oss®    2 (50%)        2 (50%)                0
  Control     1 (25%)     2 (50%)        1 (25%)                
  DBM         0           2 (50%)        2 (50%)                
                                                                
  **8**       Bio-Oss®    3 (75%)        1 (25%)                0
  Control     4 (100%)    0              0                      
  DBM         0           3 (75%)        1 (25%)                
